Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) EPS (Weighted Average and Diluted) (2022 - 2024)

CervoMed (CRVO) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with -$0.55 as the latest value for Q3 2024.

  • Quarterly EPS (Weighted Average and Diluted) rose 21.43% to -$0.55 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Sep 2024, up 82508295.51% year-over-year, with the annual reading at $2.0 million for FY2022, 4.73% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.55 in Q3 2024 for CervoMed, up from -$0.7 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.0 million in Q4 2022 to a low of -$1.7 in Q3 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged $509724.1 across 3 years, with a median of -$0.62 in 2023.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): soared 58.82% in 2023 and later increased 21.43% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at $2.0 million in 2022, then crashed by 100.0% to -$0.7 in 2023, then grew by 21.43% to -$0.55 in 2024.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CRVO at -$0.55 in Q3 2024, -$0.7 in Q3 2023, and $2.0 million in Q4 2022.